Radicava Patent Expiration

Radicava is a drug owned by Mitsubishi Tanabe Pharma Corp. It is protected by 1 US drug patent filed in 2018 out of which all have expired. Radicava's patents have been open to challenges since 05 May, 2021. Based on its patents and exclusivities, its generic launch date is estimated to be May 05, 2024. Details of Radicava's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6933310 Therapeutic agent for amyotrophic lateral sclerosis (ALS)
Nov, 2020

(4 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Radicava's patents.

Given below is the list of recent legal activities going on the following patents of Radicava.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 23 Aug, 2005 US6933310
Patent Issue Date Used in PTA Calculation 23 Aug, 2005 US6933310
Issue Notification Mailed 03 Aug, 2005 US6933310
Dispatch to FDC 29 Jun, 2005 US6933310
Application Is Considered Ready for Issue 23 Jun, 2005 US6933310
Issue Fee Payment Received 07 Jun, 2005 US6933310
Issue Fee Payment Verified 07 Jun, 2005 US6933310
Mail Notice of Allowance 24 Mar, 2005 US6933310
Notice of Allowance Data Verification Completed 23 Mar, 2005 US6933310
Miscellaneous Incoming Letter 14 Dec, 2004 US6933310


FDA has granted several exclusivities to Radicava. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Radicava, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Radicava.

Exclusivity Information

Radicava holds 4 exclusivities. All of its exclusivities have expired in 2024. Details of Radicava's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2022
Orphan Drug Exclusivity(ODE) May 05, 2024
ODE*(ODE*) May 05, 2024
Orphan Drug Exclusivity(ODE-144) May 05, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Radicava is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Radicava's family patents as well as insights into ongoing legal events on those patents.

Radicava's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Radicava's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 05, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Radicava Generic API suppliers:

Edaravone is the generic name for the brand Radicava. 5 different companies have already filed for the generic of Radicava, with Gland Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Radicava's generic

Alternative Brands for Radicava

Radicava which is used for the treatment of amyotrophic lateral sclerosis (ALS)., has several other brand drugs using the same active ingredient (Edaravone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Mitsubishi Tanabe
Radicava Ors


Apart from brand drugs containing the same ingredient, some generics have also been filed for Edaravone, Radicava's active ingredient. Check the complete list of approved generic manufacturers for Radicava





About Radicava

Radicava is a drug owned by Mitsubishi Tanabe Pharma Corp. It is used for the treatment of amyotrophic lateral sclerosis (ALS). Radicava uses Edaravone as an active ingredient. Radicava was launched by Mitsubishi Tanabe in 2017.

Approval Date:

Radicava was approved by FDA for market use on 05 May, 2017.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Radicava is 05 May, 2017, its NCE-1 date is estimated to be 05 May, 2021.

Active Ingredient:

Radicava uses Edaravone as the active ingredient. Check out other Drugs and Companies using Edaravone ingredient

Treatment:

Radicava is used for the treatment of amyotrophic lateral sclerosis (ALS).

Dosage:

Radicava is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
30MG/100ML (0.3MG/ML) SOLUTION Prescription INTRAVENOUS
60MG/100ML (0.6MG/ML) SOLUTION Prescription INTRAVENOUS